Lixte Biotech provides $6.5M secured loan to Nomad Power Systems ahead of merger close
LIXT has more than doubled off its 52-week low of $0.64 on elevated volume (3.9× avg).
Summary
Lixte Biotechnology provided a $6.5 million secured loan to its acquisition target, NOMAD Transportable Power Systems, to fund operations and repay debt ahead of their merger closing, expected around July 1, 2026.
Key Events · M&A and Partnerships · LIXT
-
Pre-Merger Financing for NOMAD
Lixte issued a $6.5 million secured promissory note to NOMAD Transportable Power Systems, Inc. on June 17, 2026, ahead of their anticipated merger closing around July 1, 2026.
-
Loan Purpose and Security
The proceeds will be used to repay NOMAD's outstanding loan obligations and for general working capital. The note is secured by a first-priority security interest in substantially all of NOMAD's assets.
-
Strategic Acquisition Support
This loan is a critical step in Lixte's pivot to AI energy infrastructure, ensuring NOMAD can accelerate commercial momentum and fulfill its order pipeline without interruption prior to the merger.
-
Merger Agreement Context
The loan is directly tied to the definitive merger agreement announced on June 16, 2026. Upon closing, the note's principal will be offset against amounts deliverable to NOMAD.
Analysis · LIXT · Life Sciences
Lixte Biotechnology Holdings, Inc. has issued a $6.5 million secured promissory note to NOMAD Transportable Power Systems, Inc. This pre-merger financing is critical for NOMAD to repay existing debt and fund working capital, ensuring its operational continuity and ability to fulfill its order backlog before the acquisition closes. This move demonstrates Lixte's commitment to the strategic pivot into AI energy infrastructure and facilitates a smoother integration and accelerated growth for the combined entity. The loan represents a significant deployment of capital relative to Lixte's market capitalization, underscoring the importance of the acquisition.
At the time of this filing, LIXT was trading at $7.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $131.6M. The 52-week trading range was $0.64 to $7.78. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.